Molecular mechanisms and clinical applications of angiogenesis

被引:4122
作者
Carmeliet, Peter [1 ,2 ]
Jain, Rakesh K. [3 ,4 ]
机构
[1] VIB, Vesalius Res Ctr, Lab Angiogenesis & Neurovasc Link, B-3000 Louvain, Belgium
[2] Katholieke Univ Leuven, Vesalius Res Ctr, Lab Angiogenesis & Neurovasc Link, B-3000 Louvain, Belgium
[3] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab Tumor Biol, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Boston, MA 02114 USA
基金
美国国家卫生研究院;
关键词
ENDOTHELIAL GROWTH-FACTOR; TUMOR VASCULATURE; VEGF-A; PROGENITOR CELLS; METASTASIS; PERICYTES; THERAPY; CANCER; PDGF; GLIOBLASTOMA;
D O I
10.1038/nature10144
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Blood vessels deliver oxygen and nutrients to every part of the body, but also nourish diseases such as cancer. Over the past decade, our understanding of the molecular mechanisms of angiogenesis (blood vessel growth) has increased at an explosive rate and has led to the approval of anti-angiogenic drugs for cancer and eye diseases. So far, hundreds of thousands of patients have benefited from blockers of the angiogenic protein vascular endothelial growth factor, but limited efficacy and resistance remain outstanding problems. Recent preclinical and clinical studies have shown new molecular targets and principles, which may provide avenues for improving the therapeutic benefit from anti-angiogenic strategies.
引用
收藏
页码:298 / 307
页数:10
相关论文
共 100 条
  • [1] Axon Guidance Molecules in Vascular Patterning
    Adams, Ralf H.
    Eichmann, Anne
    [J]. COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2010, 2 (05): : a001875
  • [2] Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08
    Allegra, Carmen J.
    Yothers, Greg
    O'Connell, Michael J.
    Sharif, Saima
    Petrelli, Nicholas J.
    Colangelo, Linda H.
    Atkins, James N.
    Seay, Thomas E.
    Fehrenbacher, Louis
    Goldberg, Richard M.
    O'Reilly, Seamus
    Chu, Luis
    Azar, Catherine A.
    Lopa, Samia
    Wolmark, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) : 11 - 16
  • [3] HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α
    Arany, Zoltan
    Foo, Shi-Yin
    Ma, Yanhong
    Ruas, Jorge L.
    Bommi-Reddy, Archana
    Girnun, Geoffrey
    Cooper, Marcus
    Laznik, Dina
    Chinsomboon, Jessica
    Rangwala, Shamina M.
    Baek, Kwan Hyuck
    Rosenzweig, Anthony
    Spiegelman, Bruce M.
    [J]. NATURE, 2008, 451 (7181) : 1008 - U8
  • [4] Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system
    Augustin, Hellmut G.
    Koh, Gou Young
    Thurston, Gavin
    Alitalo, Kari
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2009, 10 (03) : 165 - 177
  • [5] PlGF Blockade Does Not Inhibit Angiogenesis during Primary Tumor Growth
    Bais, Carlos
    Wu, Xiumin
    Yao, Jenny
    Yang, Suya
    Crawford, Yongping
    McCutcheon, Krista
    Tan, Christine
    Kolumam, Ganesh
    Vernes, Jean-Michel
    Eastham-Anderson, Jeffrey
    Haughney, Peter
    Kowanetz, Marcin
    Hagenbeek, Thijs
    Kasman, Ian
    Reslan, Hani Bou
    Ross, Jed
    Van Bruggen, Nick
    Carano, Richard A. D.
    Meng, Yu-Ju Gloria
    Hongo, Jo-Anne
    Stephan, Jean-Philippe
    Shibuya, Masabumi
    Ferrara, Napoleone
    [J]. CELL, 2010, 141 (01) : 166 - 177
  • [6] The FGF family: biology, pathophysiology and therapy
    Beenken, Andrew
    Mohammadi, Moosa
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (03) : 235 - 253
  • [7] The Notch Ligands Dll4 and Jagged1 Have Opposing Effects on Angiogenesis
    Benedito, Rui
    Roca, Cristina
    Soerensen, Inga
    Adams, Susanne
    Gossler, Achim
    Fruttiger, Marcus
    Adams, Ralf H.
    [J]. CELL, 2009, 137 (06) : 1124 - 1135
  • [8] Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
    Bergers, G
    Brekken, R
    McMahon, G
    Vu, TH
    Itoh, T
    Tamaki, K
    Tanzawa, K
    Thorpe, P
    Itohara, S
    Werb, Z
    Hanahan, D
    [J]. NATURE CELL BIOLOGY, 2000, 2 (10) : 737 - 744
  • [9] Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
    Bergers, G
    Song, S
    Meyer-Morse, N
    Bergsland, E
    Hanahan, D
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) : 1287 - 1295
  • [10] Modes of resistance to anti-angiogenic therapy
    Bergers, Gabriele
    Hanahan, Douglas
    [J]. NATURE REVIEWS CANCER, 2008, 8 (08) : 592 - 603